Sunday 18 October 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
23.44
1.63
−6.50%
Follow SRZN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 82.35 | 5.15 | 4.50 | 6.00 | 5.90 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 210.00 | 99.00 | 20.70 | 16.19 | 24.94 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 3 | 83 | 74 | 42 | 41 | 44 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.17 | 0.00 | 0.26 | 0.08 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 13 | — | 11 | 3 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 100.00 | — | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | (33) | (55) | (36) | (43) | (64) | (242) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (288.03) | 0.00 | (596.56) | (6,960.77) | |||||
| Net income | — | 0 | — | — | (33) | (55) | (36) | (43) | (64) | (242) | |||||
| Depreciation | — | — | — | — | 2 | 2 | 2 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 5.40 | 0.00 | 3.63 | 0.47 | ||||
| Earnings | — | — | — | — | (30.71) | (33.13) | (15.59) | (21.33) | (21.67) | (32.37) | |||||
| Cash flow | — | — | — | — | (27.31) | (29.64) | (19.08) | (20.00) | (6.01) | (4.04) | |||||
| Capex | — | — | — | — | (0.82) | (0.77) | (0.31) | (0.20) | (0.01) | (0.02) | |||||
| Free cash flow | — | — | — | — | (28.13) | (30.41) | (19.39) | (20.20) | (6.02) | (4.06) | |||||
| Book value | — | — | — | — | 44.39 | 66.61 | 32.84 | 18.80 | (7.29) | (25.11) | |||||
| Shares, m | — | — | — | — | 1 | 2 | 2 | 2 | 3 | 7 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | — | 0.00 | 48.61 | |||||
| P/B | — | — | — | — | — | — | 0.26 | — | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | 0.00 | 22.94 | |||||
| EV/FCF | — | — | — | — | — | — | 1.26 | — | (0.43) | (2.63) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (29) | (49) | (44) | (40) | (18) | (30) | ||||
| Capex | — | — | — | — | (1) | (1) | (1) | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | (30) | (50) | (45) | (41) | (18) | (30) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 43 | 92 | 72 | 34 | 32 | 82 | ||||
| Total debt | — | — | — | — | 10 | 8 | 6 | — | — | — | |||||
| Net debt | — | — | — | — | (49) | (102) | (76) | (36) | (35) | (89) | |||||
| Shareholders’ equity | — | — | — | — | 47 | 110 | 76 | 38 | (21) | (188) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (105.43) | (54.86) | (31.78) | (63.52) | (134.46) | (328.86) | ||||
| ROIC | — | — | — | — | 0.00 | (433.10) | (17,001.15) | (1,512.29) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | (32.72) | (69.62) | (38.78) | (75.55) | (767.91) | 231.45 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Surrozen, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AGEN Agenus Inc. | $301.7M | 2.3× | 4.1× | +34.36% (above 0%: growing) | n/m | −55.25% (below 0%: shrinking) | 100.00% | 32.72% | Compare |
| CTNM Contineum Therapeutics, Inc. | $297.2M | — (loss-making) | — | — | n/m | +26.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ARTV Artiva Biotherapeutics, Inc. | $296.3M | — (loss-making) | — (loss-making) | — | n/m | +13.60% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BNTC Benitec Biopharma Limited | $295.1M | — (loss-making) | — (loss-making) | −85.42% (below 0%: shrinking) | n/m | +38.90% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SRZN Surrozen, Inc. | $294.7M | — (loss-making) | — (loss-making) | +408.65% (above 0%: growing) | n/m | −21.25% (below 0%: shrinking) | 100.00% | (207.40%) | |
| FULC Fulcrum Therapeutics, Inc. | $280.0M | — (loss-making) | — (loss-making) | +27,018.64% (above 0%: growing) | n/m | −13.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| OCGN Ocugen, Inc. | $275.9M | — (loss-making) | — (loss-making) | +8.38% (above 0%: growing) | n/m | −13.42% (below 0%: shrinking) | 100.00% | (1,105.11%) | Compare |
| NAUT Nautilus Biotechnology, Inc. | $274.9M | — (loss-making) | — | — | n/m | −3.16% (below 0%: shrinking) | 92.11% | (8,296.32%) | Compare |
| IPSC Century Therapeutics, Inc. | $271.6M | — (loss-making) | — (loss-making) | +12,667.72% (above 0%: growing) | n/m | +26.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $287.5M | — | — | +34.36% | — | +5.22% | 100.00% | 0.00% |
Surrozen, Inc. (SRZN) key facts
- Concern: Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024.
- Surrozen, Inc. (SRZN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SRZN traded at $23.44, a market capitalization of $294.7 million.
- Return on equity was 231.5% and debt-to-equity 0.00.
- Its Altman Z-score is −7.50 (distress zone) for fiscal 2025.